


Product Name: Recombinant Human IDO (N-6His)
Catalog #: PEH0943



Summary

Name	Indoleamine 2,3-Dioxygenase/IDO/INDO
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Indoleamine 2,3-dioxygenase is produced by our E.coli expression system and the target gene encoding Met1-Gly403 is expressed with a 6His tag at the N-terminus.
Accession #	P14902
Host	E.coli
Species	Human
Predicted Molecular Mass	46.8 KDa
Formulation	Supplied as a 0.2 μm filtered solution of 20mM Sodium Acetate, 150mM NaCl, 20% Glycerol, pH 4.5.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

SDS-PAGE image



Background

Alternative Names Indole 2;3-dioxygenase; Indoleamine 2;3-dioxygenase 1; IDO-1; IDO1; IDO; INDO

Background Indoleamine 2,3-dioxygenase (IDO) is a heme enzyme that initiates the oxidative degradation of the least abundant, essential amino acid, L-tryptophan, along the kynurenine pathway. This protein is normally expressed in the dendritic cells,

Product Name: Recombinant Human IDO (N-6His)
Catalog #: PEH0943



macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. IDO activity is associated with immunosuppression and immune attenuation. Several studies showed that IDO can contribute to immune escape when expressed directly in tumor cells or when expressed in immunosuppressive antigen presenting cells such as tolerogenic dendritic cells or tumor associated macrophages. IDO also is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression.

Note

For Research Use Only , Not for Diagnostic Use.